SILK Company Profile and Key Details

Short-term trend indicators are bearishly aligned (SMA20 1.2%, SMA50 1.43%, SMA200 38.46%). The stock’s 14-day RSI is 72.04 (overbought), while the ATR of 0.12 points to tighter daily ranges. The stock remains hovering near 52-week lows, trading -0.07% below its high and over 352.14% above its low.

Silk Road Medical, Inc generated EPS of -$1.44 over the past year. Five-year average earnings growth is -3.21%. Wall Street analysts project EPS growth of 1.6% annually over the next five years. The latest quarter delivered EPS of -$0.42. The next quarter is forecast at -$0.44. Next year's EPS is expected at $2.57. Silk Road Medical, Inc earnings surprise history is a mixed track record. The quarter that ended August 07, 2024, missed forecasts by 10.53%. The prior quarter beat by -10.0%. Over the last six quarters, Apple has recorded several small beats. These include 10.26% in May 09, 2023.

Silk Road Medical, Inc has 40.63 million shares outstanding. The public float is 37.63 million shares, elevated short interest at 7.87% of float. This equals 3.15 million shares. The short ratio is 2.48 days. Institutional investors hold 101.68% of the float. Insiders own 4.15%. Buchanan Lucas W. holds 500.92 thousand shares, Davis Andrew S. has 289.71 thousand shares and Rogers Erica J. has 269.64 thousand shares.

Silk Road Medical, Inc (NASDAQ:SILK) shares are up 124.04% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Silk Road Medical, Inc trading at a premium to the broader market with a P/E of -19.14. Analyst sentiment is mixed, with the majority of ratings in Hold territory and a mean price target of $42.50, suggesting 54.6% upside. Our AI forecast model points to short-term weakness (-0.04% over two weeks), a medium-term fall (-57.69% over three months), and a longer-term loss (-55.91% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Silk Road Medical, Inc stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -0.04%, with price expected at $27.48 by October 10, 2024, within a range of $24.79 to $29.80 3-Month Outlook: Projected fall of -57.69%, reaching $11.63 by December 16, 2024, with a range of $10.23 to $12.56. 1-Year Outlook: Projected loss of -55.91%, with price at $12.12 by September 17, 2025, within a range of $9.28 to $16.47.

Silk Road Medical, Inc last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $52.54. This means the shares are trading below this model’s fair value.

Silk Road Medical, Inc (NASDAQ:SILK) closed at $27.49 USD, losing -$0.01 (-0.04%) from the previous close of $27.50. The stock is currently trading near its 52-week high $6.08 and $27.51. With a market capitalization of about $1.12 billion, Silk Road Medical, Inc is classified as a small-cap and shows higher-than-market volatility (beta ~1.54). Key stats such as the average daily volume over the past year has been around 2.06 million shares, in line with its 52-week average. Headquartered in Sunnyvale, CA, Silk Road Medical, Inc operates in the Healthcare sector and the Medical - Devices industry. Led by CEO Charles S. McKhann, the company employs approximately 474 people and listed since April 04, 2019. Silk Road Medical, Inc. operates as a medical device company in the United States.

Silk Road Medical, Inc trades at a P/E ratio of -19.14, slightly below the S&P 500 average, with a price-to-sales ratio of 6.31 and a price-to-book ratio of 7.06 trading at moderately above to book value. The P/FCF stands at -33.32, also below market averages.